Global Candidiasis Therapeutics Market 2018-2023 with DROC Analysis and Key Player Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 16, 2018--The “Global Candidiasis Therapeutics Market - Segmented by Route of Administration, Drug Type, Anatomy Type, Distribution Channel and Geography - Growth, Trends and Forecasts (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The global candidiasis therapeutics market is expected to register a CAGR of 5.5% over the forecast period. Due to high investment in healthcare and awareness of diseases, the North American segment of the market studied is estimated to account for the highest market share.
The market for systemic candidiasis is driven by an increase in the susceptible immune compromised patient pool. The high incidence of candidiasis is expected to remain a major driver for the growth of the market during the forecast period.
The Center for Disease Control and Prevention (CDC) reports that, in the United States, certain species of Candida are becoming increasingly resistant to available antifungals, such as azoles and approved echinocandins. Extensive usage of antifungals in the azole class has stimulated an increase in the number of strains of Candida that have a high rate of azole resistance. A recent US-based study found that the percentage of non-albicans Candida species increased from 46% in 2006 to 60% in 2011.
DriversIncreasing Susceptible Immune Compromised Patient Pool Growing Awareness for Candidiasis Infection
RestraintsAvailability of Alternative Treatments Narrow Pipeline Molecules Competition from Herbal Medicines and Alternate Therapies
Companies MentionedBasilea Pharmaceuticals Astellas Ferrer International Pacgen Biopharmaceuticals Novadigm Therapeutics Amplyx Pharmaceuticals Inc. Biomar Microbial Technologies Cidara Therapeutics Inc. Novabiotics Limited
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/vbm46x/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005875/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 05/16/2018 10:01 AM/DISC: 05/16/2018 10:01 AM